Clinical impact of whole-body MRI in staging and surveillance of patients with myxoid liposarcoma: a 14-year single-centre retrospective study

Samir Paruthikunnan; Natalia Gorelik; Robert E Turcotte; Sungmi Jung; Thierry Alcindor; Thomas I Powell

doi:10.1007/s00330-024-10752-1

Clinical impact of whole-body MRI in staging and surveillance of patients with myxoid liposarcoma: a 14-year single-centre retrospective study

Eur Radiol. 2024 Apr 18. doi: 10.1007/s00330-024-10752-1. Online ahead of print.

Authors

Samir Paruthikunnan¹, Natalia Gorelik², Robert E Turcotte³, Sungmi Jung⁴, Thierry Alcindor⁵, Thomas I Powell²

Affiliations

¹ York and Scarborough Teaching Hospitals NHS Foundation Trust, York, United Kingdom. samir.pm.19@gmail.com.
² Department of Radiology, McGill University Health Centre, Montreal, Canada.
³ Division of Orthopaedic Surgery, McGill University Health Centre, Montreal, Canada.
⁴ Department of Pathology, McGill University Health Centre, Montreal, Canada.
⁵ Department of Medical Oncology, McGill University Health Centre, Montreal, Canada.

PMID: 38637427
DOI: 10.1007/s00330-024-10752-1

Abstract

Objective: To assess the clinical impact of regular whole-body magnetic resonance imaging (WBMRI) surveillance in myxoid liposarcoma patients.

Methods: This was a retrospective cohort study of myxoid liposarcoma patients who underwent at least one WBMRI at our institution between October 2006 and December 2020. The effect of WBMRI on clinical management, namely treatment modification or additional diagnostic investigations was studied. A standardised WBMRI surveillance protocol was instituted in 2015. We compared patient outcomes for the metastatic patients who had and had not received regular WBMRI surveillance and performed survival analysis for both subgroups.

Results: Of the 56 patients (60.7% male, median age: 48.1 years) who underwent 345 WBMRI, 17 (30.3%) had metastases, and 168 WBMRI were performed in this group. The median imaging follow-up for the entire cohort was 35 months; the metastatic group had a median follow-up of 42 months. WBMRI changed the clinical management in 13 (76.5%) metastatic patients, with 33 instances of treatment modification. Thirty-five lesions were labelled 'indeterminate,' 16 (45.7%) had additional investigations/interventions, and 4 (11.4%) were confirmed to be metastatic. Twenty-one metastatic lesions were missed initially on WBMRI and confirmed on subsequent WBMRI, of which 5 (23.8%) were clinically significant. The 5-year survival since the detection of metastasis was better in the regular surveillance subgroup (85.7% vs. 45%), but this was not statistically significant (p = 0.068). Five patients (8.9%) developed their first metastasis more than 5 years after diagnosing the primary lesion.

Conclusion: Regular WBMRI surveillance of myxoid liposarcoma patients considerably impacts clinical management by frequently influencing treatment decisions.

Clinical relevance statement: WBMRI has been recently recommended as an imaging option for the staging and surveillance of myxoid liposarcoma patients. Our study highlights the impact of regular WBMRI surveillance on the clinical management of these patients and how it affects their survival.

Keywords: Magnetic resonance imaging; Myxoid liposarcoma; Whole-body imaging.